AbbVie Stock Drop: Understanding the Recent Market Decline

AbbVie's stock has taken a hit recently, and if you're an investor, you're likely wondering what's behind the decline. The company's quarterly earnings report revealed a 3% drop in sales, which contributed to a 10% decline in stock price.

This decline is largely due to a decrease in sales of Humira, AbbVie's top-selling medication. According to the company's own reports, Humira sales fell by 14% in the fourth quarter of last year.

The FDA's approval of biosimilars has also had a significant impact on AbbVie's stock. Biosimilars are cheaper alternatives to biologic medications like Humira, and their increasing availability has put pressure on AbbVie's sales.

AbbVie's efforts to offset the decline in Humira sales have been underway for some time. The company has been investing in its pipeline of new treatments, including a new medication for rheumatoid arthritis that has shown promising results in clinical trials.

Readers also liked: Tobacco Company Stock Code

The Motley Fool's analyst team has identified the 10 best stocks for investors to buy now, and AbbVie wasn't on the list.

Consider the potential returns of investing in the stocks that made the cut, such as Netflix and Nvidia, which have produced monster returns in the coming years.

If you invested $1,000 in Netflix in December 2004, you'd have $638,629 today.

The Motley Fool has a position in and recommends AbbVie, but it's worth considering alternative investment options that may yield higher returns.

A different take: Brk Class B Stock Fund

AbbVie's second-quarter results were a pleasant surprise, with total revenue coming in at just over $15.4 billion, a 7% increase from the year-ago result.

The company's blockbuster drugs were a major contributor to this growth, with Skyrizi sales rising 62% to $4.4 billion and Rinvoq increasing by 42% to over $2 billion.

The decline of Humira, however, was a notable exception, falling by 58% to less than $1.2 billion due to competition from biosimilars.

AbbVie's net income on a non-GAAP basis also saw a significant boost, reaching nearly $5.3 billion, or $2.97 per share, well above the year-ago profit of $4.7 billion.

This exceeded the expectations of analysts, who had predicted a revenue of around $15 billion and adjusted profitability of $2.96 per share.

AbbVie's revised guidance for 2025 is now looking even more promising, with adjusted net income expected to range from $11.88 to $12.08 per share.

Here's an interesting read: Market Price per Common Share

AbbVie has been on an acquisition spree in the past couple of years, strengthening its pipeline with several M&A deals.

It has signed several deals in the immunology space, its core area, and also made early-stage deals in oncology and neuroscience areas.

In 2024, AbbVie acquired smaller biotechs like Landos Biopharma and Celsius Therapeutics that make novel drugs for treating inflammatory bowel disease (IBD).

This has become a very popular space lately, and AbbVie is keen to capitalize on it.

It also signed a license agreement with China's FutureGen to develop a next-generation anti-TL1A antibody for IBD.

AbbVie acquired Aliada, a private biotech that makes neuroscience medicines, and announced a deal to acquire private biotech Nimble Therapeutics.

This will strengthen its immunology pipeline and give AbbVie a competitive edge in the market.

It also signed a collaboration and option-to-license agreement with EvolveImmune Therapeutics to develop next-generation cancer biotherapeutics.

And, it expanded its existing neuroscience collaboration with Gedeon Richter.

A different take: How Many Stocks Are in Brk B

Before investing $1,000 in a stock, consider the potential risks and rewards, just as the Motley Fool Stock Advisor analyst team did when they identified the 10 best stocks for investors to buy now.

AbbVie wasn't one of the top picks, but the stocks that made the cut could produce monster returns in the coming years.

If you invested $1,000 in Netflix at the time of the Motley Fool's recommendation in 2004, you'd have $638,629 by now.

Similarly, investing $1,000 in Nvidia in 2005 could have earned you $1,098,838.

The Motley Fool has a history of making successful stock recommendations, but it's essential to do your own research and consider your individual financial goals and risk tolerance before making an investment decision.

Take a look at this: Ford Class B Shares

AbbVie's stock drop is a concern for investors, but there are also some new developments worth noting. The company's sales of Humira are declining due to biosimilar erosion, with more erosion seen in Humira volume to other novel mechanisms than previously anticipated.

AbbVie has reduced its U.S. sales expectations for Humira for 2024, and sales of Juvederm fillers have declined 14.6% in the first nine months of 2024 due to slowing growth of the U.S. facial injectables market and economic headwinds in China.

Despite these challenges, AbbVie has an attractive pipeline with several early/mid-stage candidates that have blockbuster potential, including ABBV-383 and Teliso-V.

Here's an interesting read: Potential Stock Splits 2024

AbbVie's new immunology medicines, Skyrizi and Rinvoq, are performing extremely well and are bolstered by approvals for new indications.

These medicines have demonstrated compelling head-to-head data against several novel therapies in clinical studies, giving them a competitive advantage.

AbbVie expects the combined sales (risk-adjusted) of Skyrizi and Rinvoq to be more than $27 billion by 2027.

These drugs have the potential to replace Humira sales, which are declining due to the loss of exclusivity and biosimilar erosion.

AbbV's pipeline is looking incredibly promising, especially when it comes to treating blood cancers and solid tumors. They have a diverse range of therapies in the works, including ABBV-383, a BCMA CD3 bispecific being studied for relapsed/refractory multiple myeloma.

AbbV also has Teliso-V, a c-Met ADC, under review in the United States for nonsquamous non-small cell lung cancer. This is a significant development, as it could bring new hope to patients with this type of cancer.

In addition to these therapies, AbbV recently gained approval for Vyalev, a transformative treatment for advanced Parkinson’s disease. This is a major breakthrough, and it's exciting to think about the impact it could have on patients' lives.

Studies are also ongoing to evaluate new indications for Botox and Juvederm Collection of fillers. This could lead to even more uses for these popular treatments, making them even more versatile and valuable.

AbbVie's stock drop is largely due to the decline of its blockbuster drug Humira. Sales of Humira are eroding due to biosimilar competition.

The erosion in Humira's sales has been slower than expected, but AbbVie now says it's seeing more erosion than anticipated. The company reduced its U.S. sales expectations for Humira for 2024.

Juvederm sales are also declining, with a 14.6% drop in the first nine months of 2024. This is due to the slowing growth of the U.S. facial injectables market and economic headwinds in China.

The higher price point of Juvederm is also contributing to its declining sales.

AbbVie's valuation might change, but its expected earnings growth and high starting dividend yield could combine for double-digit annualized total investment returns over the next several years.

The company's P/E ratio is a relatively low 14.4 times 2025 earnings, which might already reflect the risks associated with pharmaceutical companies.

AbbVie's high-profile drug failure in late 2024 is a prime example of the risks involved in the industry.

Politics is also something to watch, with Robert F. Kennedy floating the idea of banning pharmaceutical companies from placing TV ads in the United States.

The real threat might be tariffs if they raise drug prices or complicate supply chains, but AbbVie's recent decline has made the stock a solid buy for long-term investors.

Suggestion: Snp 500 Companies